{"protocolSection": {"identificationModule": {"nctId": "NCT02805907", "orgStudyIdInfo": {"id": "300681"}, "organization": {"fullName": "MurciaSalud", "class": "OTHER_GOV"}, "briefTitle": "Efficacy of Calcifediol Supplementation in Asthma Control in Asthmatic Patients With Vitamin D Deficiency (ACViD)", "officialTitle": "Efficacy of Calcifediol Supplementation in Asthma Control in Asthmatic Patients With Vitamin D Deficiency (ACViD)", "acronym": "ACViD"}, "statusModule": {"statusVerifiedDate": "2017-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-06"}, "primaryCompletionDateStruct": {"date": "2017-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-06-13", "studyFirstSubmitQcDate": "2016-06-15", "studyFirstPostDateStruct": {"date": "2016-06-20", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-02-14", "resultsFirstSubmitQcDate": "2017-04-03", "resultsFirstPostDateStruct": {"date": "2017-06-16", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-04-03", "lastUpdatePostDateStruct": {"date": "2017-06-16", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Rub\u00e9n And\u00fajar", "investigatorTitle": "Medical Doctor. Pulmonologist", "investigatorAffiliation": "MurciaSalud"}, "leadSponsor": {"name": "MurciaSalud", "class": "OTHER_GOV"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Introduction: There are many cross-sectional studies in children and adults indicating that low vitamin D levels in asthmatic patients are correlated with poorer asthma control, poorer lung function, decreased response to glucocorticoids and more frequent exacerbations. Moreover, as there is a significant group of asthmatic patients having insufficient control of their disease, despite high doses of inhaled corticosteroids, we have investigated new treatment alternatives, which include vitamin\n\nObjective: To determine the efficacy of vitamin D supplementation in asthmatic patients with vitamin D deficiency in degree of asthma control.\n\nMaterials and methods: A prospective, controlled, randomised, triple-blind study was conducted with a follow-up of 6 months. The patients recruited were over 18 years of age with a medical diagnosis of bronchial asthma and serum 25(OH)D3 levels \\< 30 ng/ml. Patients were excluded if they had a smoking habit \u2265 10 pack-years, taking vitamin D supplements, kidney disease (creat. \\> 2 mg/dl), hypercalcaemia (corrected with proteins \\> 10.5 mg/dl), a repeat episodes of renal colic, any gastrointestinal disease that might interfere with vitamin D absorption, or severe psychosocial problems, or were pregnant or breast-feeding. The randomisation process assigned patients to one of two groups: a group that received vitamin D (in the form of calcifediol (Hidroferol\u00ae) in 16,000-IU ampoules taken weekly by the oral route) and another group that received placebo in a presentation with an identical appearance and the same administration regimen. Demographic, clinical, spirometry and laboratory endpoints were collected. The primary endpoint was degree of asthma control as determined by the internationally validated Asthma Control Test (ACT). The secondary endpoints were asthma exacerbations, dose of inhaled corticosteroids and quality of life as measured using the Mini-AQLQ (Asthma Quality of Life Questionnaire)."}, "conditionsModule": {"conditions": ["Asthma, Bronchial"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 112, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Intervention Group (IG)", "type": "EXPERIMENTAL", "description": "Calcifediol (Hidroferol\u00ae) in 16,000-IU ampoules taken weekly by the oral route", "interventionNames": ["Drug: Calcifediol"]}, {"label": "Control Group (CG)", "type": "PLACEBO_COMPARATOR", "description": "Placebo in a presentation with an identical appearance taken weekly by the oral route", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Calcifediol", "armGroupLabels": ["Intervention Group (IG)"]}, {"type": "DRUG", "name": "Placebo", "armGroupLabels": ["Control Group (CG)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Asthma Control Measured With Asthma Control Test (ACT)", "description": "Asthma Control Test (ACT): Interpretation of the ACT questionnaire: Score less than or equal to 15 points: poor control; Between 16 and 19 points: partially controlled; Greater or equal to 20 points: good control.", "timeFrame": "6 months"}], "secondaryOutcomes": [{"measure": "Number of Asthma Exacerbations", "description": "Number of asthma exacerbations during the study period", "timeFrame": "6 months"}, {"measure": "Dose Inhaled Corticosteroids as the Scale of the Spanish Guide for Asthma Management (GEMA 4.0)", "description": "Dose inhaled corticosteroids as the scale of the Spanish guide for asthma management (GEMA 4.0): Depends on the type of steroids:\n\nBeclomethasone dipropionate (Low dose: 200-500 mcg/day, Half dose: 501-1000 mcg/day, High dose: 1001-2000 mcg/day), Beclomethasone extrafine (Low dose: 100-200 mcg/day, Half dose: 201-400 mcg/day, High dose: \\> 400 mcg/day), Budesonide (Low dose: 200-400 mcg/day, Half dose: 401-800 mcg/day, High dose: 801-1600 mcg/day), Ciclesonide (Low dose: 80-160 mcg/day, Half dose: 161-320 mcg/day, High dose: 321-1280 mcg/day), Fluticasone furoate (Half dose: 92 mcg/day, High dose: 184 mcg/day), Fluticasone propionate (Low dose: 100-250 mcg/day, Half dose: 251-500 mcg/day, High dose: 501-1000 mcg/day), Mometasone furoate (Low dose: 100-200 mcg/day, Half dose: 201-400 mcg/day, High dose: 401-800 mcg/day),", "timeFrame": "6 months"}, {"measure": "Quality of Life Measured With Mini-AQLQ (Asthma Quality of Life Questionnaire)", "description": "Mini-AQLQ (Asthma Quality of Life Questionnaire): The response options for each item are placed on an equidistant 7-point scale, where 1 = maximum limitation and 7 = no limitation. The questionnaire Global score, which is the mean for all 15 items that make up the scale, and a score for each dimension, which is the average of the corresponding items for that dimension.", "timeFrame": "6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Medical diagnosis of bronchial asthma\n* serum 25(OH)D3 levels \\< 30 ng/ml.\n\nExclusion Criteria:\n\n* smoking habit \u2265 10 pack-years,\n* taking vitamin D supplements,\n* kidney disease (creat. \\> 2 mg/dl),\n* hypercalcaemia (corrected with proteins \\> 10.5 mg/dl),\n* repeat episodes of renal colic,\n* any gastrointestinal disease that might interfere with vitamin D absorption,\n* severe psychosocial problems,\n* pregnant\n* breast-feeding", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Rub\u00e9n And\u00fajar Espinosa, Medicine", "affiliation": "MurciaSalud", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Servicio Murciano de Salud", "city": "Murcia", "zip": "30008", "country": "Spain", "geoPoint": {"lat": 37.98704, "lon": -1.13004}}]}, "referencesModule": {"references": [{"pmid": "24838406", "type": "RESULT", "citation": "Castro M, King TS, Kunselman SJ, Cabana MD, Denlinger L, Holguin F, Kazani SD, Moore WC, Moy J, Sorkness CA, Avila P, Bacharier LB, Bleecker E, Boushey HA, Chmiel J, Fitzpatrick AM, Gentile D, Hundal M, Israel E, Kraft M, Krishnan JA, LaForce C, Lazarus SC, Lemanske R, Lugogo N, Martin RJ, Mauger DT, Naureckas E, Peters SP, Phipatanakul W, Que LG, Sheshadri A, Smith L, Solway J, Sullivan-Vedder L, Sumino K, Wechsler ME, Wenzel S, White SR, Sutherland ER; National Heart, Lung, and Blood Institute's AsthmaNet. Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. JAMA. 2014 May;311(20):2083-91. doi: 10.1001/jama.2014.5052."}, {"pmid": "33154023", "type": "DERIVED", "citation": "Andujar-Espinosa R, Salinero-Gonzalez L, Illan-Gomez F, Castilla-Martinez M, Hu-Yang C, Ruiz-Lopez FJ. Effect of vitamin D supplementation on asthma control in patients with vitamin D deficiency: the ACVID randomised clinical trial. Thorax. 2021 Feb;76(2):126-133. doi: 10.1136/thoraxjnl-2019-213936. Epub 2020 Nov 5."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Intervention Group (IG)", "description": "Calcifediol (Hidroferol\u00ae) in 16,000-IU ampoules taken weekly by the oral route\n\nCalcifediol"}, {"id": "FG001", "title": "Control Group (CG)", "description": "Placebo in a presentation with an identical appearance taken weekly by the oral route\n\nPlacebo"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "56"}, {"groupId": "FG001", "numSubjects": "56"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "53"}, {"groupId": "FG001", "numSubjects": "53"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Intervention Group (IG)", "description": "Calcifediol (Hidroferol\u00ae) in 16,000-IU ampoules taken weekly by the oral route\n\nCalcifediol"}, {"id": "BG001", "title": "Control Group (CG)", "description": "Placebo in a presentation with an identical appearance taken weekly by the oral route\n\nPlacebo"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "56"}, {"groupId": "BG001", "value": "56"}, {"groupId": "BG002", "value": "112"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.57", "spread": "15.83"}, {"groupId": "BG001", "value": "56.61", "spread": "15.00"}, {"groupId": "BG002", "value": "55.59", "spread": "15.39"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "87"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "25"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "56"}, {"groupId": "BG001", "value": "56"}, {"groupId": "BG002", "value": "112"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Spain", "categories": [{"measurements": [{"groupId": "BG000", "value": "56"}, {"groupId": "BG001", "value": "56"}, {"groupId": "BG002", "value": "112"}]}]}]}, {"title": "Initial Asthma Control Test (ACT)", "description": "Interpretation of the ACT questionnaire: Score less than or equal to 15 points: poor control; Between 16 and 19 points: partially controlled; Greater or equal to 20 points: good control.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "units on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "17.71", "spread": "4.54"}, {"groupId": "BG001", "value": "19.02", "spread": "4.59"}, {"groupId": "BG002", "value": "18.37", "spread": "4.59"}]}]}]}, {"title": "Initial Asthma Quality of Life Questionnaire", "description": "The response options for each item are placed on an equidistant 7-point scale, where 1 = maximum limitation and 7 = no limitation. The questionnaire Global score, which is the mean for all 15 items that make up the scale, and a score for each dimension, which is the average of the corresponding items for that dimension.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "units on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4.38", "spread": "1.62"}, {"groupId": "BG001", "value": "4.85", "spread": "1.96"}, {"groupId": "BG002", "value": "4.62", "spread": "1.91"}]}]}]}, {"title": "Asthma Severity", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Intermitent", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "17"}]}, {"title": "Mild Persistent", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "20"}]}, {"title": "Moderate Persistent", "measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "56"}]}, {"title": "Severe Persistent", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "19"}]}]}]}, {"title": "Exacerbations", "description": "Number of exacerbations in the last 6 months", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Exacerbations in the last 6 months", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.18", "spread": "1.55"}, {"groupId": "BG001", "value": "1.14", "spread": "2.70"}, {"groupId": "BG002", "value": "1.16", "spread": "2.19"}]}]}]}, {"title": "Hospitalizations", "description": "Number of hospitalizations in the last 6 months", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Hospitalizations in the last 6 months", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.11", "spread": "0.31"}, {"groupId": "BG001", "value": "0.13", "spread": "0.33"}, {"groupId": "BG002", "value": "0.12", "spread": "0.32"}]}]}]}, {"title": "Emergency care", "description": "Number of emergency care in the last 6 months", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Emergency care in the last 6 months", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.45", "spread": "0.81"}, {"groupId": "BG001", "value": "0.59", "spread": "1.30"}, {"groupId": "BG002", "value": "0.52", "spread": "1.08"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Asthma Control Measured With Asthma Control Test (ACT)", "description": "Asthma Control Test (ACT): Interpretation of the ACT questionnaire: Score less than or equal to 15 points: poor control; Between 16 and 19 points: partially controlled; Greater or equal to 20 points: good control.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Intervention Group (IG)", "description": "Calcifediol (Hidroferol\u00ae) in 16,000-IU ampoules taken weekly by the oral route\n\nCalcifediol"}, {"id": "OG001", "title": "Control Group (CG)", "description": "Placebo in a presentation with an identical appearance taken weekly by the oral route\n\nPlacebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20.49", "spread": "4.13"}, {"groupId": "OG001", "value": "18.23", "spread": "5.70"}]}]}]}, {"type": "SECONDARY", "title": "Number of Asthma Exacerbations", "description": "Number of asthma exacerbations during the study period", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Asthma exacerbations", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Intervention Group (IG)", "description": "Calcifediol (Hidroferol\u00ae) in 16,000-IU ampoules taken weekly by the oral route\n\nCalcifediol"}, {"id": "OG001", "title": "Control Group (CG)", "description": "Placebo in a presentation with an identical appearance taken weekly by the oral route\n\nPlacebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1", "spread": "0.20"}, {"groupId": "OG001", "value": "0", "spread": "0.4"}]}]}]}, {"type": "SECONDARY", "title": "Dose Inhaled Corticosteroids as the Scale of the Spanish Guide for Asthma Management (GEMA 4.0)", "description": "Dose inhaled corticosteroids as the scale of the Spanish guide for asthma management (GEMA 4.0): Depends on the type of steroids:\n\nBeclomethasone dipropionate (Low dose: 200-500 mcg/day, Half dose: 501-1000 mcg/day, High dose: 1001-2000 mcg/day), Beclomethasone extrafine (Low dose: 100-200 mcg/day, Half dose: 201-400 mcg/day, High dose: \\> 400 mcg/day), Budesonide (Low dose: 200-400 mcg/day, Half dose: 401-800 mcg/day, High dose: 801-1600 mcg/day), Ciclesonide (Low dose: 80-160 mcg/day, Half dose: 161-320 mcg/day, High dose: 321-1280 mcg/day), Fluticasone furoate (Half dose: 92 mcg/day, High dose: 184 mcg/day), Fluticasone propionate (Low dose: 100-250 mcg/day, Half dose: 251-500 mcg/day, High dose: 501-1000 mcg/day), Mometasone furoate (Low dose: 100-200 mcg/day, Half dose: 201-400 mcg/day, High dose: 401-800 mcg/day),", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Intervention Group (IG)", "description": "Calcifediol (Hidroferol\u00ae) in 16,000-IU ampoules taken weekly by the oral route\n\nCalcifediol"}, {"id": "OG001", "title": "Control Group (CG)", "description": "Placebo in a presentation with an identical appearance taken weekly by the oral route\n\nPlacebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"categories": [{"title": "Low", "measurements": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "24"}]}, {"title": "Half", "measurements": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "23"}]}, {"title": "High", "measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "6"}]}]}]}, {"type": "SECONDARY", "title": "Quality of Life Measured With Mini-AQLQ (Asthma Quality of Life Questionnaire)", "description": "Mini-AQLQ (Asthma Quality of Life Questionnaire): The response options for each item are placed on an equidistant 7-point scale, where 1 = maximum limitation and 7 = no limitation. The questionnaire Global score, which is the mean for all 15 items that make up the scale, and a score for each dimension, which is the average of the corresponding items for that dimension.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Intervention Group (IG)", "description": "Calcifediol (Hidroferol\u00ae) in 16,000-IU ampoules taken weekly by the oral route\n\nCalcifediol"}, {"id": "OG001", "title": "Control Group (CG)", "description": "Placebo in a presentation with an identical appearance taken weekly by the oral route\n\nPlacebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.34", "spread": "1.29"}, {"groupId": "OG001", "value": "4.64", "spread": "1.56"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "6 months", "eventGroups": [{"id": "EG000", "title": "Intervention Group (IG)", "description": "Calcifediol (Hidroferol\u00ae) in 16,000-IU ampoules taken weekly by the oral route\n\nCalcifediol", "deathsNumAffected": 0, "deathsNumAtRisk": 56, "seriousNumAffected": 0, "seriousNumAtRisk": 56, "otherNumAffected": 3, "otherNumAtRisk": 56}, {"id": "EG001", "title": "Control Group (CG)", "description": "Placebo in a presentation with an identical appearance taken weekly by the oral route\n\nPlacebo", "deathsNumAffected": 0, "deathsNumAtRisk": 56, "seriousNumAffected": 0, "seriousNumAtRisk": 56, "otherNumAffected": 2, "otherNumAtRisk": 56}], "otherEvents": [{"term": "dyspepsia", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 56}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 56}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Rub\u00e9n And\u00fajar-Espinosa", "organization": "MurciaSalud", "email": "rubemed@hotmail.com", "phone": "0034669500052"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}, {"id": "D000014808", "term": "Vitamin D Deficiency"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000001361", "term": "Avitaminosis"}, {"id": "D000003677", "term": "Deficiency Diseases"}, {"id": "D000044342", "term": "Malnutrition"}, {"id": "D000009748", "term": "Nutrition Disorders"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M17551", "name": "Vitamin D Deficiency", "asFound": "Vitamin D Deficiency", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M4660", "name": "Avitaminosis", "relevance": "LOW"}, {"id": "M6879", "name": "Deficiency Diseases", "relevance": "LOW"}, {"id": "M25306", "name": "Malnutrition", "relevance": "LOW"}, {"id": "M12684", "name": "Nutrition Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000002112", "term": "Calcifediol"}], "ancestors": [{"id": "D000014815", "term": "Vitamins"}, {"id": "D000018977", "term": "Micronutrients"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000050071", "term": "Bone Density Conservation Agents"}], "browseLeaves": [{"id": "M17550", "name": "Vitamin D", "relevance": "LOW"}, {"id": "M6003", "name": "Cholecalciferol", "relevance": "LOW"}, {"id": "M17558", "name": "Vitamins", "relevance": "LOW"}, {"id": "M5375", "name": "Calcifediol", "asFound": "Cholecystitis", "relevance": "HIGH"}, {"id": "M21009", "name": "Micronutrients", "relevance": "LOW"}, {"id": "M16885", "name": "Trace Elements", "relevance": "LOW"}, {"id": "T479", "name": "Vitamin D3", "relevance": "LOW"}, {"id": "T442", "name": "Cholecalciferol", "relevance": "LOW"}, {"id": "T440", "name": "Calciferol", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Micro", "name": "Micronutrients"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Vi", "name": "Vitamins"}]}}, "hasResults": true}